Insights into pharma market evaluation and product lifecycle strategies. From assessing drug production viability to choosing the right markets for expansion.
Most people evaluate opportunities by market size. But market size alone does not determine whether a business can survive. What truly matters is whether your operating model can convert demand into sustainable revenue that covers your costs.
In the world of Business Development (BD), I’ve observed a fascinating difference between the "Western" and "Taiwanese" approach: Is it better to aim first, or fire immediately?
Learn how to find and develop high-value clients in CDMO business development, from global conferences to LinkedIn. Practical tactics for 6–24 month sales cycles, with real lessons on technical positioning, trust-building, and resilience.
Practical strategies for Regional CDMOs to accelerate to global market and overcome Western biotech hesitation. Learn how specialization, GMP certifications, strategic partnerships, and industry networking can help small to mid-sized CDMOs become trusted partners in US, EU, and Japanese markets
Despite solid technology and competitive pricing, many Asian CDMOs struggle to win global clients. Here explores 5 deep-rooted structural barriers — regulatory hurdles, reputation building, geopolitical risks, communication challenges — prevent Asian CDMOs from achieving true globalization.
